Reporter brief
Senolytic and anti-fibrotic agents tested to enhance stem cell therapy for knee osteoarthritis in RCT
What happened
This prospective, randomized, double-blind, active-control trial evaluated whether a senolytic agent (Fisetin) and an anti-fibrotic agent (Losartan), used independently and in combination, could improve the effect of autologous bone marrow aspirate concentrate (BMAC) injection into osteoarthritic knees. The abstract provided reports the trial design and intervention structure but does not report results, efficacy outcomes, or safety findings.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Rct; Human.
Patients with osteoarthritis of the knee
- Design
- Rct
- Sample
- —
- Journal
- Steadman Philippon Research Institute
- Published
- Apr 16, 2024
Effect size
Not recorded.
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Stem cell therapy timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.